Skip to main content
. 2001 Nov;159(5):1895–1904. doi: 10.1016/S0002-9440(10)63036-2

Figure 5.

Figure 5.

The ACE inhibitor quinapril improves persistent proteinuria in WT with moderate (a) and severe (b) overload nephropathy. WT treated with quinapril (WT Tx) were significantly protected from persistent proteinuria in moderate overload nephropathy (at day 7: 62 ± 6 versus 515 ± 411 mg/dl, n = 3 to 5, *P < 0.05; at day 11: 88 ± 42 versus 776 ± 366, n = 3 to 5, **P < 0.01) (a). In severe overload nephropathy, treated WT reproduced the same beneficial effects on persistent proteinuria as AT1(−/−) (at day 7: 550 ± 209 versus 2492 ± 394, n = 4, **P < 0.01; at day 11: 105 ± 69 versus 1420 ± 1183, n = 5, ***P < 0.05) (b). Early peak of proteinuria in AT1(−/−) was significantly delayed by quinapril in severe overload model (at day 1: 92 ± 48 versus 1268 ± 634, n = 4 to 5, *P < 0.01).